Role of genetic and molecular profiling in sarcomas.
The treatment of sarcomas has been challenging due to their heterogeneity, rarity in the general population, relative insensitivity to chemotherapeutics, and lack of effective targeted agents. One of the first major breakthroughs in the treatment of sarcomas was the use of imatinib to treat gastrointestinal stromal tumors (GISTs). Since then, advanced molecular techniques and genetic profiling have revolutionized the approach to sarcoma classification, diagnosis, prognosis and, most importantly, treatment. As the sarcoma genetic database continues to expand, the basis for how we classify, diagnose, and treat these challenging malignancies will be redefined. The overall goal of these types of techniques has been to determine a molecular blueprint for each sarcoma subtype and discover actionable alterations that lend themselves to targeted therapies. Other important information derived from these large genomic databases includes biomarkers, prognostic indicators, and information regarding tumorigenesis. Eventually, advanced molecular techniques will provide a personalized-medicine approach that tailors each treatment regimen to the patient's own tumor genome.
Department of Internal Medicine, Temple University Hospital, 3401 North Broad Street, Philadelphia, PA, 19140, USA, scott.norberg@tuhs.temple.edu.
Scott M
SM
Norberg
Sujana
S
Movva
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D046152:Gastrointestinal Stromal Tumors / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics; D020869:Gene Expression Profiling; D006801:Humans; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D058990:Molecular Targeted Therapy / Q000639:trends*; D057285:Precision Medicine / Q000639:trends*; D011379:Prognosis; D012509:Sarcoma / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics
D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate